– Positive, updated Phase 2 SOLSTICE data showed combination of tobevibart and elebsiran is well tolerated and achieved undetectable HDV RNA in 88% of chronic hepatitis delta participants evaluable at ...

Agreement underscores Norgine's mission to bring innovative therapies to patients and builds on our heritage in hepatology and specialty pharmaceuticals. Vir Biotechnology's chronic hepatitis delta ...

SAN FRANCISCO, December 16, 2025--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading ...

Microsoft announced new agents for Word, Excel, and PowerPoint. They can help to shrink the gap between ideation and production. Other Copilot updates include an expanded Voice mode. In the era of AI ...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) ...

SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination ...

I've been testing PC and mobile software for more than 20 years, focusing on photo and video editing, operating systems, and web browsers. Prior to my current role, I covered software and apps for ...

The Trump administration told a judge that it would use contingency funds to pay at least some SNAP benefits during the ongoing U.S. government shutdown. SNAP provides food stamps to about 42 million ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination of tobevibart and elebsiran in ...

Explore the art of jewelry making with our beginner-friendly tutorial on crafting a simple beaded chain link bracelet. Inspired by celestial themes like the eclipse, moon, and sun, this ...